Table 2.
Bisphosphonate use and mortality
| Incidence rate/100 person-years (number of deaths) | ||||
|---|---|---|---|---|
| Cohort | BP | Control | HR (95% CI) | P |
| Entire eligible cohort | ||||
| Unadjusted | 7.5 (1460) | 17.5 (24962) | 0.45 (0.43–0.48) | < 0.001 |
| Adjusted for age and sex | 0.66 (0.62–0.70) | < 0.001 | ||
| Adjusted for age, sex, medications and diagnoses | 0.70 (0.66–0.74) | < 0.001 | ||
| Adjusted for age, sex, medications, diagnoses, length of hospitalization, type of hip fracture, known/suspected dementia, and physical functioning status* | 0.85 (0.80–0.90) | < 0.001 | ||
| Matched cohort | ||||
| Total | 7.9 (1313) | 9.4 (1609) | 0.85 (0.79–0.91) | < 0.001 |
| Alendronate | 7.7 (1167) | 9.5 (1486) | 0.82 (0.76–0.89) | < 0.001 |
| Risedronate | 8.3 (83) | 9.4 (69) | 0.84 (0.61–1.15) | 0.27 |
| Zoledronic acid | 11.2 (48) | 7.7 (45) | 1.51 (1.00–2.28) | 0.048 |
BP bisphosphonate, HR hazard ratio, CI confidence interval
*Physical functioning status includes the following variables: admitted from private home, discharged to private home, use of walking aid before fracture, walking ability before fracture, and American Society of Anesthesiologists physical status score